Skip to main content

Global Newsroom

CSL Behring Patient Zahra Khan, living with hereditary angioedema

Global Newsroom

Recent News Releases

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

Feb 12, 2024

Strong CSL Behring portfolio growth especially Ig FINANCIAL HIGHLIGHTS4 Revenue $8.05 billion, up 11% at CC3 NPAT $1.90 billion1, up 17% NPAT $1.94 billion1 at CC3, up 20% NPATA $2.02 billion1,2 ,...

Read more news from CSL

Recent News Releases
Jan 16, 2024

Findings show that convenience of treatment and flexibility of administration, such as at-home treatment options, are of high importance to patients KING OF PRUSSIA, Pa., Jan. 16, 2024...

Read more news from CSL Behring

Recent News Releases
Sep 26, 2023

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

Read more news from CSL Seqirus

Recent News Releases
Feb 23, 2024

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe...

Read more news from CSL Vifor

Read all company news releases

Media Resources

Media Contacts

CSL 
Victoria, Australia
Phone: +61 450 909 211
Email: media@csl.com.au

CSL Behring
North America
Email: MediaNorthAmerica@cslbehring.com

Europe
Email: MediaEurope@cslbehring.com

Asia Pacific
Email: MediaAsiaPacific@cslbehring.com

CSL Seqirus
EMEA and Latam
Emmanuella Dekonor
Phone: +44 7920500496
Email: Emmanuella.Dekonor@seqirus.com

North America
Tiffany Cody
Phone: +1 908 370 1863
Email: Tiffany.Cody@seqirus.com

Asia Pacific
Hamish Walsh
Phone: 0422 424 338
Email: Hamish.Walsh@seqirus.com

CSL Plasma
United States
Plasma.Communications@CSLPLASMA.COM

Follow Us Online
  • linkedin icon
  • twitter icon
  • youtube icon
  • facebook icon
  • instagram icon
Get our latest news releases in your inbox
* Required Fields